Biogen (Mexico) Insiders
| BIIB Stock | MXN 3,267 142.15 4.55% |
Biogen employs about 9.6 K people. The company is managed by 10 executives with a total tenure of roughly 35 years, averaging almost 3.0 years of service per executive, having 961.0 employees per reported executive. Break down of Biogen's management performance can provide insight into the company performance.
| Robin Kramer President Chief Accounting Officer, Vice President |
| Sanjay Jariwala President Senior Vice President - Worldwide Medical |
Biogen |
Biogen Management Team Effectiveness
The company has return on total asset (ROA) of 0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.Biogen holds a total of 144 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Biogen in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Biogen, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Biogen Workforce Comparison
Biogen Inc is number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers - Major industry is currently estimated at about 209,134. Biogen holds roughly 9,610 in number of employees claiming about 5% of equities under Drug Manufacturers - Major industry.
The company has Profit Margin (PM) of 0.28 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29. Biogen Inc Benchmark Summation
The output start index for this execution was one with a total number of output elements of sixty. The Lowest value over a specified period line plots minimum value of Biogen Inc price series.
Biogen Notable Stakeholders
A Biogen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biogen often face trade-offs trying to please all of them. Biogen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biogen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robin Kramer | Chief Accounting Officer, Vice President | Profile | |
| Sanjay Jariwala | Senior Vice President - Worldwide Medical | Profile | |
| Ginger Gregory | Chief Human Resource Officer, Executive Vice President | Profile | |
| Anabella Villalobos | Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | Profile | |
| Christopher Viehbacher | CEO Pres | Profile | |
| Susan Esq | Chief VP | Profile | |
| Michael CPA | Ex CFO | Profile | |
| Natacha Gassenbach | Chief Affairs | Profile | |
| Nicole Murphy | Head Technology | Profile | |
| Michael Hencke | Head Relations | Profile |
About Biogen Management Performance
The success or failure of an entity such as Biogen Inc often depends on how effective the management is. Biogen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biogen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biogen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. BIOGEN INC operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 7800 people.
Please note, the imprecision that can be found in Biogen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biogen Inc. Check Biogen's Beneish M Score to see the likelihood of Biogen's management manipulating its earnings.
Biogen Workforce Analysis
Traditionally, organizations such as Biogen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biogen within its industry.Biogen Manpower Efficiency
Return on Biogen Manpower
| Revenue Per Employee | 1.1M | |
| Revenue Per Executive | 1.1B | |
| Net Income Per Employee | 161.9K | |
| Net Income Per Executive | 155.6M |
Additional Tools for Biogen Stock Analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.